Remdesivir

Characteristics and mechanism

Chemically, remdesivir is administered as a prodrug that converts in cells to an active nucleoside triphosphate. The active metabolite resembles adenosine and competes with natural nucleotides during viral RNA synthesis, causing premature chain termination or delayed interruption of the polymerase reaction. It shows in vitro activity against several RNA viruses and was considered for various emerging viral diseases before being tested extensively in SARS‑CoV‑2 infection.

Development and early history

Remdesivir was originally developed and tested as a treatment for Ebola virus disease and for other RNA viral infections. While it did not become a standard therapy for Ebola, the compound had demonstrated antiviral effects in laboratory and some animal studies, which supported rapid repurposing when SARS‑CoV‑2 emerged in 2019. The drug has been supplied under investigational or emergency use pathways in several countries while formal trials were conducted.

Clinical trials and regulatory decisions

During the COVID‑19 pandemic remdesivir was the subject of multiple randomized clinical trials and large pragmatic studies. Early randomized data from a U.S. National Institutes of Health–led trial reported a reduction in median time to recovery among hospitalized patients receiving remdesivir compared with placebo. In contrast, the WHO Solidarity trial, a large international study involving thousands of patients, found little or no effect on overall mortality. These differing outcomes prompted debate about the drug's role and the appropriate patient populations and timing for treatment.

• Notable outcomes: some trials showed shorter time to clinical improvement; other large studies found no clear mortality benefit.
• Regulatory actions: because of the public health emergency, authorities issued emergency or conditional authorizations for use; some later granted formal approval for use in hospitalized patients under specific indications. See regulatory notices at regulatory sources.

Uses, administration and safety

Remdesivir is given by intravenous infusion, typically in a hospital setting, and is intended for patients with confirmed viral infection who require hospitalization and supplemental oxygen in many jurisdictions. Typical treatment duration in trials has ranged from five to ten days depending on clinical status. Commonly reported adverse effects include elevated liver enzymes and gastrointestinal symptoms; clinicians monitor liver function and other parameters during therapy. Cautions have been raised about use in patients with severe renal impairment due to the vehicle used in some formulations.

Practical considerations and notable facts

Because trial results differed, remdesivir is often considered within a broader treatment strategy that may include corticosteroids for patients with respiratory failure and supportive care. Cost, availability, and regulatory recommendations vary by country. Clinical guidelines and hospital protocols help determine which patients are most likely to benefit; for practical guidance on formulation and dosing see clinical resources at treatment guidance. Scientific discussion continues about optimal timing, combinations with other therapies, and patient selection.

For historical and research context, reviewers and clinicians refer to peer‑reviewed trial reports and public health summaries; summaries of early and ongoing research are available from research repositories and public health organizations studying antiviral therapies for emerging infections (research summaries).